Nerve Blocks and Neurolysis for Pain Management
Customize your policy alerts
Sign up for Arizona Complete Health Policy CP.MP.170 alerts
Get alerted when Policy CP.MP.170 changes without checking for updates manually.
Monitor payer policy activity
Clinical coverage criteria for peripheral nerve blocks, sympathetic blocks, celiac plexus blocks/neurolysis, intercostal and peripheral/ganglion blocks, occipital nerve blocks, and intraosseous basivertebral nerve ablation for non-Medicare plans affiliated with Centene/AZ Complete Health.
No material clinical or coverage changes in this revision.
Coverage Criteria — Nerve Blocks & Neurolysis
Occipital Nerve Block — Diagnostic and Therapeutic
Covered when ALL of the following are met
Initial injection for diagnosis
Therapeutic blocks limited
Celiac Plexus Nerve Block/Neurolysis
Medically necessary for either indication A or B below
Celiac neurolysis as opioid-sparing option
Intercostal Nerve Block/Neurolysis
Covered when ALL of the following are met
Intercostal blocks for these neuropathic etiologies considered medically necessary
Peripheral/Ganglion Nerve Blocks
Covered when specified criteria are met
Therapeutic injections requirement
Not Medically Necessary / Insufficient Evidence
Not supported
Not supported
Excluded indications
Extracted clinical coverage observations
Coverage considerations and clinical observations extracted from the document (no full claim criteria present in this excerpt):
Document patient response and consider alternatives if repeat requested
Consider in patients refractory to other therapies
Use cautiously; prognostic block response should be documented before ablation
Document MRI Modic changes
In addition to the core diagnostic and therapeutic criteria for occipital nerve blocks, the policy specifies that occipital blocks are intended primarily for suspected occipital neuralgia with pain in the distribution of the greater, lesser and/or third occipital nerves, associated dysesthesia/allodynia, and either tenderness over affected nerve branches or a trigger point at the emergence of the greater occipital nerve. Therapeutic blocks require documentation of temporary relief from a prior injection and failure of a 3‑month conservative therapy trial (heat/rest/physical therapy, NSAIDs unless contraindicated, an oral anticonvulsant or tricyclic antidepressant, and activity modification). The frequency limit for occipital therapeutic injections is no more than four injections within 12 months (includes diagnostic injection).
Policy revision history documents that the indication for sympathetic nerve block in ischemic limb pain was changed from “limited evidence to support” to “not medically necessary.” This change is recorded in the policy’s revision notes and should be considered when reviewing prior approvals or request rationale.
Coverage is guided by this clinical policy but remains subject to the enrollee’s benefit document terms, exclusions, and limitations. Where conflicts arise, applicable state Medicaid provisions or Medicare NCD/LCD requirements take precedence and must be followed. This policy does not guarantee payment and providers should verify benefit terms and any prior authorization requirements prior to service.
Additional sympathetic nerve blocks beyond the first or second are allowed only when there is documented immediate benefit from an initial block (e.g., improved temperature or decreased pain) and injections are spaced at least one week apart. The policy also states there is insufficient evidence to support genicular nerve blocks, neurolysis, and radiofrequency neurotomy, as well as intraosseous basivertebral nerve ablation (Intracept), and therefore these procedures are not supported by evidence of safety and effectiveness.
For celiac plexus neurolysis, pooled data show meaningful initial pain relief in many patients with pancreatic cancer, but the policy notes that repeat neurolysis is effective only about 30% of the time and is therefore discouraged. Providers should document the clinical response to a prior celiac plexus intervention and consider alternative management strategies before requesting repeat neurolysis.
Required Conservative Treatment Before Procedures
Must have failed — 3 months conservative therapy (occipital)
Required prior to therapeutic occipital block
Must have failed — 3e=3 weeks requirement
Required prior to initial sympathetic block
Documentation of failure of 3e=6 months conservative therapy
Required prior to intraosseous basivertebral nerve ablation
Procedure Frequency, Interval, and Repeat Rules
CPT / Device / Reference Codes
| 64400 | Injection(s), anesthetic agent(s) and/or steroid; trigeminal nerve, each branch |
| 64405 | Injection(s), anesthetic agent(s) and/or steroid; greater occipital nerve |
| 64408 | Injection(s), anesthetic agent(s) and/or steroid; vagus nerve |
| 64415 | Injection(s), anesthetic agent(s) and/or steroid; brachial plexus, including imaging guidance, when performed |
| 64417 | Injection(s), anesthetic agent(s) and/or steroid; axillary nerve, including imaging guidance, when performed |
| 64418 | Injection(s), anesthetic agent(s) and/or steroid; suprascapular nerve |
| 64420 | Injection(s), anesthetic agent(s) and/or steroid; intercostal nerve, single level |
| 64421 | Injection(s), anesthetic agent(s) and/or steroid; intercostal nerve, each additional level |
| 64425 | Injection(s), anesthetic agent(s) and/or steroid; ilioinguinal, iliohypogastric nerves |
| 64430 | Injection(s), anesthetic agent(s) and/or steroid; pudendal nerve |
| 64454 | Injection(s), anesthetic agent(s) and/or steroid; genicular nerve branches, including imaging guidance, when performed |
| 64505 | Injection, anesthetic agent; sphenopalatine ganglion |
| 64510 | Injection, anesthetic agent; stellate ganglion (cervical sympathetic) |
| 64517 | Injection, anesthetic agent; superior hypogastric plexus |
| 64520 | Injection, anesthetic agent; lumbar or thoracic (paravertebral sympathetic) |
| 64530 | Injection, anesthetic agent; celiac plexus, with or without radiologic monitoring |
| 64600 | Destruction by neurolytic agent, trigeminal nerve; supraorbital, infraorbital, mental, or inferior alveolar branch |
| 64605 | Destruction by neurolytic agent, trigeminal nerve; second and third division branches at foramen ovale |
| 64610 | Destruction by neurolytic agent, trigeminal nerve; second and third division branches at foramen ovale under radiologic monitoring |
| 64620 | Destruction by neurolytic agent, intercostal nerve |
| 64624 | Destruction by neurolytic agent, genicular nerve branches including imaging guidance, when performed |
| 64628 | Thermal destruction of intraosseous basivertebral nerve; first 2 vertebral bodies, lumbar or sacral |
| 64629 | Thermal destruction of intraosseous basivertebral nerve; each additional vertebral body |
| 64640 | Destruction by neurolytic agent; other peripheral nerve or branch |
| 64680 | Destruction by neurolytic agent, with or without radiologic monitoring; celiac plexus |
| 64999 | Unlisted procedure, nervous system |
| 510(k) | FDA 510(k) premarket notification referenced for Intracept Intraosseous Nerve Ablation System |
| L36850 | Local coverage determination: peripheral nerve blocks (example cited) |
| L39420 | Local coverage determination: thermal destruction of the intraosseous basivertebral nerve (BVN) |
| A57788 | Local coverage article: peripheral nerve blocks |
| L33933 | Local coverage determination: peripheral nerve blocks (older LCD cited) |
Provider Billing, Documentation, and Prior Authorization Actions
Intraoperative peripheral nerve blocks — code with primary procedure
If peripheral/ganglion nerve blocks are performed intraoperatively or “as part of a surgery or other procedure,” code them with the primary surgical/procedural code and do not bill them separately for prior authorization or separate payment.
- Follow proper coding practices: include the block in the primary procedure claim rather than submitting a separate PA request for the block.
Prior authorization may be required for referenced neurolysis/ablation CPT codes
Certain neurolysis and ablation CPT codes referenced in the policy may require prior authorization per payer rules; providers should verify PA requirements for these codes before scheduling services.
Check Health Plan administrative policies and benefits for PA requirements
Prior authorization requirements are governed by the Health Plan’s administrative policies and the member’s benefit documents; providers must check PA requirements before performing services.
- Verify plan-specific PA rules and benefit limits prior to service.
- State Medicaid or Medicare NCD/LCD requirements may supersede this policy—review those rules when applicable.
Conservative therapy must be documented prior to therapeutic blocks
Therapeutic occipital and celiac plexus procedures require documented failure of prior conservative therapy before proceeding with therapeutic injections or neurolysis.
- Occipital therapeutic blocks: documentation of failed 3 months of conservative treatment (heat/rest/PT, NSAIDs unless contraindicated, oral anticonvulsant or tricyclic antidepressant therapy, and activity modification).
- Celiac plexus: used when opioids are no longer effective or intolerable; chronic pancreatitis indication requires prior refractory therapy and, for repeat blocks, ≥3 months since prior injection with documented clinical benefit.
Document provider-level procedural requirements before authorization/claim
Ensure all procedure-specific provider actions and requirements in this policy are documented in the medical record before requesting authorization or submitting claims.
- Document that procedures were performed by appropriately trained clinicians when relevant (e.g., sympathetic blocks managed by pain specialists for CRPS).
- Follow coding guidance when blocks are performed with or as part of another procedure.
Administrative reminder — confirm coding, contracts, and guidance
Administrative reminders: confirm coding matches clinical indication and that claims follow plan/provider contract terms.
- Reference current CPT descriptions and professional coding guidance prior to claim submission.
- Claims submission must comply with the Health Plan contract and benefit terms.
Occipital block — required clinical documentation elements
Occipital nerve block documentation must include pain distribution and characteristics, evidence of dysesthesia/allodynia and either tenderness or a trigger point, and for therapeutic blocks record prior temporary relief and three months of failed conservative therapy.
- Document unilateral or bilateral pain in the distribution of greater/lesser/third occipital nerves and at least two characteristic features (e.g., severe intensity, shooting/stabbing quality).
- For therapeutic blocks, record numeric pain reduction after prior injection and failure of the 3-month conservative therapy regimen listed in the policy.
Sympathetic block — required documentation for CRPS
For sympathetic nerve blocks in CRPS, document diagnosis, management by an experienced pain specialist, active rehabilitation, failure of ≥3 weeks of conservative therapies, and two or more objective findings in the affected extremity.
- Objective findings include hyperalgesia/allodynia; edema or sweating changes/asymmetry; temperature asymmetry >1°C or skin color changes; decreased ROM, motor dysfunction, or trophic changes.
- Additional sympathetic blocks require documentation of immediate positive response to the first or second block and blocks given at least one week apart.
Celiac plexus block/neurolysis — required documentation elements
For celiac plexus block/neurolysis for pancreatic cancer or chronic pancreatitis, document diagnosis, severity of visceral abdominal/back pain, and that opioids are ineffective or not tolerated (for cancer); for chronic pancreatitis document nondilated duct and prior response if repeat is requested.
- Pancreatic cancer indication: diagnosis of pancreatic cancer with severe visceral abdominal/back pain and opioid ineffectiveness or intolerability; exclude somatic malignancy in related innervation areas.
- Chronic pancreatitis indication: refractory pain with non-dilated pancreatic duct; repeat block allowed only if ≥3 months since prior injection and there was clinical benefit.
Document prior block response and include CPT codes for repeat groin blocks
For post-herniorrhaphy groin pain, document the patient’s positive response to the initial diagnostic block and include the CPT code(s) used when requesting repeat therapeutic blocks.
- Include examples of CPTs used (policy examples: 64420–64421 for intercostal nerve, 64450/64454 for peripheral nerves) and note injections may be given every 1–3 weeks while relief is developing.
- Document imaging ruled out non‑neuropathic causes and that less invasive methods failed prior to the first diagnostic block.
Align documentation and claims with policy, benefit terms, and external rules
Ensure clinical documentation and coding align with this clinical policy, the member’s benefit terms, and any applicable state Medicaid or Medicare NCD/LCD requirements when submitting claims.
- When state Medicaid or Medicare rules conflict with this policy, those rules take precedence; review applicable NCDs/LCDs prior to applying policy criteria.
- Align submitted CPT codes and clinical notes to support medical necessity under the Health Plan’s benefit terms.
Denial risk — additional sympathetic blocks without documented benefit
Additional sympathetic nerve blocks without documented benefit from the first or second block are considered not medically necessary and may be denied.
- Additional blocks must be given at least one week apart and require an immediate positive response to the first or second block (e.g., improved temperature ≥1.5°C and decreased pain) to be considered medically necessary.
Denial risk — repeat celiac plexus procedures without specified indications
Repeat celiac plexus nerve blocks or neurolysis for indications other than the specified pancreatic cancer or chronic pancreatitis criteria are not medically necessary and may be denied.
- Repeat neurolysis is discouraged for unspecified indications due to low effectiveness; repeat chronic pancreatitis blocks allowed only when ≥3 months since prior injection and clinical benefit was documented.
Coding listed in policy does not guarantee coverage
Inclusion or exclusion of CPT codes in this policy is informational only and does not guarantee coverage; providers should reference up-to-date coding guidance prior to claim submission.
- CPT codes and descriptions are provided for informational purposes; always verify current professional coding guidance and payer rules before billing.
Denial triggers — benefit limits and external coverage rules may override policy
Coverage and denial decisions are subject to the Health Plan’s benefit terms, exclusions and limitations, administrative policies, and applicable state or Medicare coverage rules; discrepancies defer to those governing requirements.
- Review the member’s evidence of coverage and plan-level administrative procedures prior to treatment.
- For Medicare members, applicable NCDs/LCDs and Coverage Articles should be reviewed before applying policy criteria.
Imaging & Technique Requirements
Imaging optional for general invasive pain management procedures
Imaging guidance is optional for many invasive pain management procedures; the policy allows procedures with or without radiographic guidance and permits only one procedure per visit.
- Policy states procedures may be performed with or without radiographic guidance and that the patient receives only one procedure per visit.
Recommend imaging guidance for intercostal, peripheral nerve injections, and neurolysis when specified
Ultrasound or radiologic monitoring is recommended when performing intercostal nerve blocks, peripheral nerve injections, and neurolysis where CPT descriptions specify imaging to minimize complications and improve dermatomal coverage.
- Intercostal blocks can be performed with ultrasound guidance to reduce intravascular injection and pneumothorax risk and to increase reliable dermatomal coverage.
- Many CPT codes include imaging guidance when performed.
Refer to cited guidelines and LCDs for any additional imaging or technique requirements
Cited clinical guidelines and CMS Local Coverage Determinations or articles referenced in the policy may include additional imaging or technique requirements; refer to those sources and the policy's referenced LCDs for specifics.
- Review the referenced guidelines and LCDs for procedure-specific imaging or technique stipulations that may apply to Medicare members.
Background — Mechanism and Scope
Nerve blocks temporarily interrupt peripheral nerve conduction by injection of a local anesthetic and may be used for diagnostic, therapeutic, or prognostic purposes. Diagnostic blocks help confirm the source of pain when distribution and clinical features are consistent (for example, occipital blocks for occipital neuralgia). Therapeutic blocks provide temporary analgesia and may reduce opioid requirements or improve function when conservative measures fail. Prognostic blocks (for example, prior to neurolytic procedures or ablation) can help predict response to more definitive interventions.
Key Definitions
Services Not Covered / Exclusions
The policy identifies several procedures as not covered or insufficiently supported by evidence: occipital nerve block for the diagnosis or treatment of migraine and cervicogenic headaches is considered not medically necessary; genicular nerve blocks, neurolysis and genicular radiofrequency neurotomy lack sufficient evidence of safety and effectiveness; and intraosseous basivertebral (Intracept) radiofrequency ablation is unsupported by adequate evidence for chronic low back pain in this policy.
The policy reiterates that peripheral nerve blocks used for prevention or treatment of various headache types, including migraine and other cranial neuralgias, are considered not medically necessary because effectiveness has not been established. It also emphasizes that peripheral/ganglion nerve blocks administered as part of a surgical procedure should be coded with the primary procedure and are not billed separately.
Genicular nerve procedures and intraosseous basivertebral nerve ablation remain categorized as having insufficient evidence to determine safety and effectiveness; thus these are not supported indications within this policy. The policy references the lack of high-quality peer‑reviewed literature to justify routine coverage for these interventions.
For peripheral/ganglion nerve blocks the policy specifies covered scenarios (for example, malignant pain and post‑herniorrhaphy neuralgia when diagnostic and therapeutic criteria are met) but clarifies that blocks for headaches and trigeminal neuralgia are not medically necessary or lack sufficient evidence. Providers should ensure documentation supports the covered indication and meet the stated diagnostic or therapeutic criteria.
The policy notes that coding updates have been made and that certain neurolytic and ablation CPT codes are discussed in the document; however, inclusion of a code does not guarantee coverage. Coding and payment for intraosseous basivertebral procedures (e.g., Intracept) are referenced but the clinical evidence in this policy is judged insufficient to support coverage.
The policy’s revision history explicitly records that the indication of sympathetic nerve block for ischemic leg pain was changed to “not medically necessary.” This change is reflected in the policy split and updates documented in the revision notes.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.